Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889944 | PMC |
| http://dx.doi.org/10.1016/j.jdin.2025.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.
J Eur Acad Dermatol Venereol
March 2025
Department of Dermatology and Allergy, University Hospital, LMU, Munich, Germany.
Background: Phase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head-to-head in phase III studies.
Objective: To evaluate the relative efficacy and safety of biologics for HS in a network meta-analysis including available data from phase III trials.
Methods: MEDLINE and Embase were searched for phase III trials investigating the efficacy and/or safety of at least one biologic for moderate-to-severe HS.
Response to "Hidradenitis suppurativa electronic medical record (EPIC) tool: A convenient tool of hidradenitis suppurativa specialty clinics".
JAAD Int
April 2025
Department of Dermatology, University of Southern California, Los Angeles, California.
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS.
Acta Derm Venereol
March 2025
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Hidradenitis suppurativa is a chronic skin disease associated with significant disease burden. To assess patients' treatment benefits, disease-specific outcomes measurement is needed. This study aimed to develop a questionnaire called Patient Benefit Index for hidradenitis suppurativa (PBI-HS).
View Article and Find Full Text PDFHidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity.
JID Innov
May 2025
Miami HS Center, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Hidradenitis suppurativa tunnel structures lined with epithelium within the dermis are unique features of advanced disease stages that significantly impair patients' QOL. The presence of hidradenitis suppurativa tunnels is associated with a decreased likelihood of achieving a clinical response, even when receiving biological therapy. The cellular and molecular mechanisms underlying tunnel formation and pathology are only partially understood, which hampers the development of more effective targeted therapies.
View Article and Find Full Text PDFManaging Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors.
Dermatol Clin
April 2025
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, PCAM 7 South, Room 724, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address:
"Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant quality-of-life impact. In addition to the 2 drugs approved by the Food and Drug Administration for HS, adalimumab and secukinumab, several other biologic and small molecule inhibitors are used off-label or are in clinical trials. A systematic and evidence-based approach using these and other therapies-considering patient comorbidities, response to therapy, dose adjustment, and frequent troubleshooting-is required.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!